Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene to Start Trial of PD-L1/4-1BB Bispecific in Solid Tumors and NHL

publication date: Jul 22, 2021

Shanghai's Antengene was approved to start an Australian Phase I trial of its PD-L1/4-1BB bispecific antibody. The trial will evaluate the safety and tolerability of ATG-101 as a single agent in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Antengene, which developed ATG-101 in-house and continues to hold global rights to the candidate, plans to file INDs for China and US trials of ATG-101 later this year. More details....

Stock Symbol: (HK: 6996)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here